Literature DB >> 24923984

Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.

Veronica Serra1, Liana Fattore, Maria Scherma, Roberto Collu, Maria Sabrina Spano, Walter Fratta, Paola Fadda.   

Abstract

RATIONALE: Salvinorin A is a recreational drug derived from Salvia divinorum, a sage species long used as an entheogen. While salvinorin A has potent hallucinogenic properties, its abuse potential has not been assessed consistently in controlled behavioural and neurochemical studies in rodents.
OBJECTIVE: This study aimed to assess salvinorin A abuse potential by measuring its capacity to establish and maintain self-administration behaviour and to modify dopamine (DA) levels in the nucleus accumbens (NAcc) of rats.
RESULTS: Male Lister Hooded (LH) and Sprague-Dawley (SD) rats were allowed to self-administer salvinorin A (0.5 or 1.0 μg/kg/infusion) intravenously 2 h/day for 20 days under a continuous schedule of reinforcement and lever pressing as operandum. LH rats discriminated between the active and inactive levers but did not reach the acquisition criterion for stable self-administration (≥12 active responses vs ≤5 inactive responses for at least 5 consecutive days). SD rats discriminated between the two levers at the lower dose only but, like LH rats, never acquired stable self-administration behaviour. Systemic salvinorin A increased extracellular DA in the NAcc shell of both LH (at ≥40 μg/kg) and SD rats (at ≥5 μg/kg), but injection into the ventral tegmental area (VTA) induced no significant change in NAcc DA concentration in LH rats and only brief elevations in SD rats.
CONCLUSIONS: Salvinorin A differs from other commonly abused compounds since although it affects accumbal dopamine transmission, yet it is unable, at least at the tested doses, to sustain stable intravenous self-administration behaviour.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24923984     DOI: 10.1007/s00213-014-3641-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.

Authors:  Christopher R McCurdy; Kenneth J Sufka; Grant H Smith; Jason E Warnick; Marcelo J Nieto
Journal:  Pharmacol Biochem Behav       Date:  2006-01-23       Impact factor: 3.533

2.  Persistent psychosis associated with salvia divinorum use.

Authors:  Peter Przekop; Timothy Lee
Journal:  Am J Psychiatry       Date:  2009-07       Impact factor: 18.112

3.  Salvinorin A: allosteric interactions at the mu-opioid receptor.

Authors:  Richard B Rothman; Daniel L Murphy; Heng Xu; Jonathan A Godin; Christina M Dersch; John S Partilla; Kevin Tidgewell; Matthew Schmidt; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2006-10-23       Impact factor: 4.030

Review 4.  Catecholamine theories of reward: a critical review.

Authors:  R A Wise
Journal:  Brain Res       Date:  1978-08-25       Impact factor: 3.252

Review 5.  Drugs and reinforcement mechanisms: a critical review of the catecholamine theory.

Authors:  H C Fibiger
Journal:  Annu Rev Pharmacol Toxicol       Date:  1978       Impact factor: 13.820

Review 6.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

7.  Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.

Authors:  Bryan A Killinger; Mary M Peet; Lisa E Baker
Journal:  Pharmacol Biochem Behav       Date:  2010-05-20       Impact factor: 3.533

8.  Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat.

Authors:  Paola Fadda; Maria Scherma; Alessandra Fresu; Maria Collu; Walter Fratta
Journal:  Synapse       Date:  2003-10       Impact factor: 2.562

9.  Antidepressive effects of the κ-opioid receptor agonist salvinorin A in a rat model of anhedonia.

Authors:  Mitchell T Harden; Staci E Smith; Jennifer A Niehoff; Christopher R McCurdy; George T Taylor
Journal:  Behav Pharmacol       Date:  2012-10       Impact factor: 2.293

10.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

View more
  5 in total

Review 1.  Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; David P Siderovski
Journal:  Anesth Analg       Date:  2021-02-01       Impact factor: 6.627

Review 2.  Kappa Opioids, Salvinorin A and Major Depressive Disorder.

Authors:  George T Taylor; Francesca Manzella
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 3.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03

Review 4.  Dopamine Circuit Mechanisms of Addiction-Like Behaviors.

Authors:  Carli L Poisson; Liv Engel; Benjamin T Saunders
Journal:  Front Neural Circuits       Date:  2021-11-09       Impact factor: 3.492

Review 5.  Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Front Pharmacol       Date:  2015-09-08       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.